0001140361-23-051135.txt : 20231102 0001140361-23-051135.hdr.sgml : 20231102 20231102161102 ACCESSION NUMBER: 0001140361-23-051135 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20231030 ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20231102 DATE AS OF CHANGE: 20231102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kronos Bio, Inc. CENTRAL INDEX KEY: 0001741830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39592 FILM NUMBER: 231372402 BUSINESS ADDRESS: STREET 1: 1300 S. EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN MATEO STATE: CA ZIP: 94402 BUSINESS PHONE: (650) 781-5200 MAIL ADDRESS: STREET 1: 1300 S. EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN MATEO STATE: CA ZIP: 94402 8-K 1 ef20013915_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  October 30, 2023

 
Kronos Bio, Inc.
(Exact name of registrant as specified in its charter)


Delaware
001-39592
82-1895605
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

1300 So. El Camino Real, Suite 400
San Mateo, California
  
94402
(Address of principal executive offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code: (650) 781-5200
 
N/A
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
         
Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered
Common Stock, $0.001 par value per share
   KRON
   The Nasdaq Stock Market LLC
 
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.05
Costs Associated with Exit or Disposal Activities.

On October 30, 2023, the Board of Directors of Kronos Bio, Inc. (the “Company”) approved an approximately 19% reduction of its workforce as part of a strategic resource allocation, restructuring and cost containment plan. The workforce reduction is expected to be completed on November 2, 2023.

In connection with the reduction in workforce, the Company expects to incur charges of approximately $1.8 million associated with cash severance payments in the fourth quarter of 2023, and up to approximately $0.3 million in charges associated with cash payments for COBRA reimbursement over as much as the next six months.

Item 7.01
Regulation FD Disclosure.

As a result of the strategic resource allocation, restructuring and cost containment plan referenced under Item 2.05 above, the Company expects that its existing resources will be sufficient to support the Company’s planned operations into 2026.

The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Forward-Looking Statements
Statements in this report that are not statements of historical fact are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This report, in some cases, uses terms such as “expect,” “plan,” “will,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the expected timing for the completion of the reduction in workforce; the expected charges to be incurred and the related cash payments and the timing thereof; the sufficiency of the Company’s existing resources to support its planned operations into 2026; and other statements that are not historical fact. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: changes to the assumptions on which the estimated charges associated with the reduction in workforce are based; unintended consequences from the reduction in workforce; changes in the macroeconomic environment or competitive landscape that impact the Company’s business; whether the Company will be able to progress its clinical trials on the timelines anticipated, including due to risks inherent in the clinical development of novel therapeutics; risks related to the Company’s limited experience as a company in conducting clinical trials; the risk that results of preclinical studies and early clinical trials (including preliminary results) are not necessarily predictive of future results; and risks associated with the sufficiency of the Company’s cash resources and need for additional capital. These and other risks are described in greater detail in the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed with the SEC on August 8, 2023. Any forward-looking statements that are made in this report speak only as of the date of this report and are based on management’s assumptions and estimates as of such date. Except as required by law, the Company assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this report.

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
KRONOS BIO, INC.




By:
/s/ Norbert Bischofberger


Norbert Bischofberger, Ph.D.


President and Chief Executive Officer
Dated: November 2, 2023
 


EX-101.SCH 2 kron-20231030.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 kron-20231030_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 4 kron-20231030_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Oct. 30, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 30, 2023
Entity File Number 001-39592
Entity Registrant Name Kronos Bio, Inc.
Entity Central Index Key 0001741830
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 82-1895605
Entity Address, Address Line One 1300 So. El Camino Real
Entity Address, Address Line Two Suite 400
Entity Address, City or Town San Mateo
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94402
City Area Code 650
Local Phone Number 781-5200
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol KRON
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
XML 6 ef20013915_8k_htm.xml IDEA: XBRL DOCUMENT 0001741830 2023-10-30 2023-10-30 false 0001741830 8-K 2023-10-30 Kronos Bio, Inc. DE 001-39592 82-1895605 1300 So. El Camino Real Suite 400 San Mateo CA 94402 650 781-5200 false false false false Common Stock, $0.001 par value per share KRON NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://kronosbio.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ef20013915_8k.htm kron-20231030.xsd kron-20231030_lab.xml kron-20231030_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20013915_8k.htm": { "nsprefix": "kron", "nsuri": "http://kronosbio.com/20231030", "dts": { "inline": { "local": [ "ef20013915_8k.htm" ] }, "schema": { "local": [ "kron-20231030.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "labelLink": { "local": [ "kron-20231030_lab.xml" ] }, "presentationLink": { "local": [ "kron-20231030_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://kronosbio.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20231030to20231030", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20013915_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20231030to20231030", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20013915_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://kronosbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 13 0001140361-23-051135-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-23-051135-xbrl.zip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end